Pfizer to deliver 10% more doses to US by end of May
WorldFILE PHOTO: A healthcare worker prepares a Pfizer coronavirus disease (COVID-19) vaccination in Los Angeles, California, U.S., January 7, 2021. REUTERS/Lucy Nicholson/File Photo14 Apr 2021 05:05AMShare this contentBookmarkNEW YORK: Pfizer has ramped up production of its COVID-19 vaccine and can deliver 10 per cent more doses to the United States by the end of May, Chief Executive Officer Albert Bourla said in a tweet on Tuesday.
Pfizer will supply the full 300 million doses two weeks earlier than expected, Bourla said Read more: CNA »
Singapore sees ‘several important lessons’ from Tan Tock Seng Hospital COVID-19 cluster
SINGAPORE: Singapore has learnt 'several important lessons' from the COVID-19 cluster at Tan Tock Seng Hospital (TTSH), among them - that the ...
Thailand negotiating to buy 5-10 million doses of Pfizer COVID-19 vaccine: PMThailand is negotiating to buy five to 10 million doses of the COVID-19 vaccine developed by Pfizer Inc and BioNTech, the country's prime minister ...
EU to get 50 million Pfizer doses early as US prolongs J&J pauseThe European Union said Wednesday that it is expecting 50 million Pfizer coronavirus vaccine doses earlier than expected, as the United States said it would continue a pause in vaccinations using the Johnson & Johnson shot for at least another week so regulators can assess possible blood clot links.
Stuff To Watch This Week (May 10-16, 2021)
South African variant may evade protection from Pfizer vaccine, Israeli study saysJERUSALEM (Reuters) -The coronavirus variant discovered in South Africa may evade the protection provided by Pfizer /BioNTech's COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is very low and the research has not been peer reviewed. The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel's largest healthcare provider, Clalit. But among patients who had received two doses of the vaccine, the variant's prevalence rate was eight times higher than those unvaccinated - 5.4% versus 0.7%.
US authorises Pfizer/BioNTech Covid-19 vaccine for children 12 to 15